Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
anabolic steroid
|
| gptkbp:ATCCode |
A14AA08
|
| gptkbp:brand |
gptkb:oxandrolone
|
| gptkbp:broadcastOn |
gptkb:Schedule_III_(US)
|
| gptkbp:chemicalFormula |
C19H30O3
|
| gptkbp:controlledSubstanceSchedule |
gptkb:United_States
|
| gptkbp:developedBy |
gptkb:Searle_Laboratories
|
| gptkbp:eliminationHalfLife |
9 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Anavar
|
| gptkbp:introducedIn |
1964
|
| gptkbp:legalStatus |
prescription only (US)
|
| gptkbp:marketedAs |
gptkb:Oxandrin
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
306.4 g/mol
|
| gptkbp:notableFor |
low risk of estrogenic side effects
mild androgenic effects popular in bodybuilding |
| gptkbp:prohibits |
gptkb:World_Anti-Doping_Agency
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
hair loss
acne liver toxicity testosterone suppression cholesterol changes |
| gptkbp:usedFor |
gptkb:bone
severe burns muscle wasting diseases weight gain after surgery |
| gptkbp:bfsParent |
gptkb:oxandrolone
|
| gptkbp:bfsLayer |
8
|